BEAT - NASDAQ
HeartBeam, Inc.
$1.47
+8.1%HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
At a Glance
Live SnapshotHeartBeam, Inc. Management Team
Dr. Lance Myers Ph.D.
Chief Artificial Intelligence Scientist
Mr. Robert P. Eno
Chief Executive Officer, Chief Business Officer & Director
Compensation
$490,675
Mr. Timothy Cruickshank
Chief Financial Officer
Compensation
$422,663
Mr. Kenneth Persen
Chief Technology Officer
Compensation
$371,776
Mr. Richard M. Ferrari
Executive Chairman
Compensation
$145,000
Dr. Branislav Vajdic Ph.D.
Founder, President & Director
Compensation
$626,804
Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.
Member of Scientific Advisory Board & Chief Medical Officer
Ms. Richa Gujarati
Senior Vice President of Product
HeartBeam, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.08M worth of BEAT shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
307.1K
1.08M
-1.1M
-$1.08M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Strome Mark E
10 Percent Owner
$895K
De Urioste George
Director
$182K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.08M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
BEAT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | May 29, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 30, 2024 | April 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 26, 2023 | May 26, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 11, 2022 | September 30, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | May 02, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.